Author:
Mellatyar Hassan,Sattari Sina,Asl Amir Nezami,Akbarzadeh Abolfazl
Publisher
Springer Science and Business Media LLC
Reference129 articles.
1. June, C. H., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365.
2. June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), 64–73.
3. Sadelain, M., Rivière, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423–431.
4. Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discovery, 3(4), 388–398.
5. Kochenderfer, J. N., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood, The Journal of the American Society of Hematology, 119(12), 2709–2720.